Endocrine research · 2024
Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vodanović Ivana Dora, Barač Nekić Anja, Šambula Lana, Zibar Tomšić Karin, Dušek Tina, Kaštelan Darko
Аннотация
BACKGROUND: Mitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events.
METHODS: A retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane.
RESULTS: Mitotane toxicity was present in all patients (100%). Two (7.7%) patients developed 1-3 adverse events, 15 (57.7%) experienced 4-6 adverse events and 9 (34.6%) patients had more than 6 adverse events. Two (7.7%) patients discontinued mitotane due to adverse events.
CONCLUSION: Careful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.
METHODS: A retrospective analysis of adverse events was performed in 26 ACC patients adjuvantly treated with mitotane.
RESULTS: Mitotane toxicity was present in all patients (100%). Two (7.7%) patients developed 1-3 adverse events, 15 (57.7%) experienced 4-6 adverse events and 9 (34.6%) patients had more than 6 adverse events. Two (7.7%) patients discontinued mitotane due to adverse events.
CONCLUSION: Careful monitoring and timely management are essential for ensuring mitotane treatment adherence and maximizing its benefits.